News

1 Underrated Reason to Buy This Market-Beating Stock
Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...
The Bakersfield Californian2d
Access Barriers Hamper Early Line Adoption of UCB’s Bimzelx at Six Months Post-Launch in ...
Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful ...